JP2025524557A5 - - Google Patents

Info

Publication number
JP2025524557A5
JP2025524557A5 JP2024577399A JP2024577399A JP2025524557A5 JP 2025524557 A5 JP2025524557 A5 JP 2025524557A5 JP 2024577399 A JP2024577399 A JP 2024577399A JP 2024577399 A JP2024577399 A JP 2024577399A JP 2025524557 A5 JP2025524557 A5 JP 2025524557A5
Authority
JP
Japan
Prior art keywords
groups
group
pharmaceutically acceptable
bifunctional compound
androgen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024577399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025524557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/103576 external-priority patent/WO2024002206A1/en
Publication of JP2025524557A publication Critical patent/JP2025524557A/ja
Publication of JP2025524557A5 publication Critical patent/JP2025524557A5/ja
Pending legal-status Critical Current

Links

JP2024577399A 2022-06-30 2023-06-29 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法 Pending JP2025524557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263357054P 2022-06-30 2022-06-30
US63/357,054 2022-06-30
PCT/CN2023/103576 WO2024002206A1 (en) 2022-06-30 2023-06-29 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same

Publications (2)

Publication Number Publication Date
JP2025524557A JP2025524557A (ja) 2025-07-30
JP2025524557A5 true JP2025524557A5 (https=) 2025-12-16

Family

ID=89383152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024577399A Pending JP2025524557A (ja) 2022-06-30 2023-06-29 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法
JP2024577397A Pending JP2025520909A (ja) 2022-06-30 2023-06-29 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024577397A Pending JP2025520909A (ja) 2022-06-30 2023-06-29 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法

Country Status (11)

Country Link
US (3) US20250197409A1 (https=)
EP (2) EP4547667A1 (https=)
JP (2) JP2025524557A (https=)
KR (2) KR20250027728A (https=)
CN (2) CN119487035A (https=)
AU (2) AU2023300784A1 (https=)
CA (2) CA3259653A1 (https=)
IL (1) IL318001A (https=)
MX (2) MX2024015832A (https=)
TW (2) TWI893405B (https=)
WO (3) WO2024002289A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118955474A (zh) * 2024-07-29 2024-11-15 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记的巴德卡鲁胺及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
CA2988414C (en) * 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
IL312367A (en) * 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
EP3658548A1 (en) * 2017-07-28 2020-06-03 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
IL302595A (en) * 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
WO2020211822A1 (zh) * 2019-04-18 2020-10-22 成都海创药业有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
CN114829342A (zh) * 2019-12-23 2022-07-29 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
WO2021143816A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021231927A1 (en) * 2020-05-14 2021-11-18 The Regents Of The University Of Michigan Androgen receptor protein degraders with a tricyclic cereblon ligand
WO2022011205A1 (en) * 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
KR20220014952A (ko) * 2020-07-29 2022-02-08 한국화학연구원 안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
CN114163444B (zh) * 2020-09-11 2023-07-14 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
JP2023547084A (ja) * 2020-10-21 2023-11-09 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体タンパク質の標的分解のための化合物および方法

Similar Documents

Publication Publication Date Title
CA3219236A1 (en) Exatecan derivatives and antibody-drug conjugates thereof
US10280183B2 (en) Therapeutic agent for treating tumors
RU2013156687A (ru) Антагонисты рецептора св1
JP2018528156A (ja) シリコン系薬物複合体及びその使用方法
US20200384110A1 (en) Biocompatible photothermal composition for treatment of cancer and skin diseases
JP2009504748A5 (https=)
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JP2025524557A5 (https=)
JP2006507220A5 (https=)
US20130225870A1 (en) Method of synthesizing substituted 2-alkyl phenols
CN103230596A (zh) 一种具有协同抗肿瘤作用的金纳米药物载体
US20120269903A1 (en) Novel mannopyranoside derivatives with anticancer activity
RU2002130247A (ru) Производные оксадиазола, обладающие противоопухолевым действием
JP2025520909A5 (https=)
WO2021254453A1 (zh) 氨基吡啶类化合物
TW202246254A (zh) 聯芳組成物和調控激酶級聯之方法
TW202438043A (zh) 具有可降解頭之可離子化脂質
CN106279138B (zh) 芳杂环类衍生物及其在药物中的应用
JP2025508881A (ja) アリールアルキンアミド誘導体
ES2277138T3 (es) Compuestos esteroideos con actividad antitumoral.
JP2022551457A (ja) 抗がん剤に対して細胞を感作する新規のカルバゾール誘導体
US12049474B2 (en) Nucleoside prodrugs and uses related thereto
JP2023520883A5 (https=)
ES2265583T3 (es) 2"-oxo-voruscharina y derivados de la misma.
CN121039138A (zh) 双脂质结构